Market access requirements in China for medical devices include mandatory registration with the National Medical Products Administration (NMPA), compliance with China’s tiered classification system, submission of technical documentation, and, in many cases, locally conducted clinical data. Foreign manufacturers must appoint a China-based authorized representative and meet labelling requirements in Mandarin. The sections below unpack each requirement in detail.
Who regulates medical devices in China?
Medical devices in China are regulated by the National Medical Products Administration (NMPA), the central authority responsible for reviewing, approving, and supervising medical products on the Chinese market. The NMPA was restructured from the former China Food and Drug Administration (CFDA) in 2018, though the term CFDA medical device still appears in older documentation and industry references.
Under the NMPA, the Center for Medical Device Evaluation (CMDE) handles the technical review of registration applications. Provincial-level NMPA offices manage lower-risk device registrations and play a role in post-market supervision. Together, these bodies form the core of China’s medical device regulatory framework, which has undergone significant reform since 2017 to align more closely with international standards while retaining China-specific requirements.
How are medical devices classified in China?
China uses a three-tier classification system for medical devices based on the level of risk they present. Class I devices carry the lowest risk and require only filing (registration filing) at the provincial level. Class II devices carry moderate risk and require registration with provincial NMPA offices. Class III devices present the highest risk and require registration directly with the national NMPA.
The classification of a device determines the entire regulatory pathway, the depth of technical documentation required, and whether clinical evaluation or clinical trials are needed. China’s classification catalogue is periodically updated, and devices that are novel or do not fit existing categories may require a classification determination before registration can proceed. Misclassification is a common source of delay, so confirming the correct class early is essential for any China medical device market entry strategy. To learn more about how we approach these challenges, visit our services overview.
What is the NMPA registration process for foreign manufacturers?
Foreign manufacturers seeking NMPA approval must appoint a China-based authorized representative, known as a Registration Agent, who acts as the legal liaison with the NMPA. The registration application is submitted in the name of this agent on behalf of the overseas manufacturer. All documentation must be provided in Mandarin Chinese.
The core registration dossier typically includes:
- Product description and technical documentation
- Risk management documentation
- Summary of preclinical and clinical data
- Quality management system certificate (ISO 13485 or equivalent GMP certificate)
- Evidence of approval in the country of origin (for Class II and III devices)
- Labelling and instructions for use in Chinese
The NMPA requires that the manufacturer’s quality management system has been inspected and certified, and for Class III devices, an on-site inspection of the manufacturing facility by NMPA inspectors is typically required. This inspection adds time and preparation effort to the overall process and is a step that foreign manufacturers frequently underestimate.
What clinical data does China require for device approval?
China requires clinical evaluation for most Class II and all Class III medical devices. Historically, the NMPA mandated that clinical trials be conducted within China, even when robust overseas data existed. Regulatory reforms introduced in recent years have created pathways to use overseas clinical data, but acceptance is not automatic and depends on whether the clinical environment and patient population are considered comparable.
For devices for which overseas data is submitted, manufacturers must provide a detailed clinical evaluation report demonstrating that the data is applicable to the Chinese population and clinical context. If the NMPA determines that local data is still necessary, a clinical trial must be conducted in NMPA-approved Chinese clinical trial institutions. The NMPA maintains a list of accepted clinical trial sites, and trial protocols require NMPA review and approval before initiation.
Certain device categories benefit from exemptions from clinical trials, particularly where sufficient clinical literature exists and the device is well-established internationally. Checking the current exemption catalogue early in the planning phase can significantly reduce timelines and cost. Our team has extensive experience navigating these determinations — find out more about who we are on our company page.
What are the labelling and post-market requirements in China?
All medical devices sold in China must carry labelling in Mandarin Chinese that meets NMPA requirements. Labels must include the product name, registration certificate number, manufacturer information, intended use, warnings, and storage conditions, among other mandatory elements. Instructions for use must also be provided in Chinese and are reviewed as part of the registration dossier.
Post-market obligations for registered devices include:
- Adverse event reporting to the NMPA within defined timelines depending on severity
- Annual reporting on device safety and performance
- Post-market surveillance and complaint handling
- Notifying the NMPA of significant changes to the device, manufacturing process, or intended use, which may trigger a variation application or re-registration
- Maintaining the registration certificate, which must be renewed every five years
China’s post-market regulatory framework has strengthened considerably in recent years, with the NMPA increasing enforcement activity. Distributors and the authorized representative share responsibility for post-market compliance in China, making it important to have clear contractual arrangements in place before market entry.
How long does it take to get market access in China?
The timeline for China medical device registration varies significantly by device class and complexity. Class I device filings can be completed in a matter of weeks. Class II registrations typically take 12 to 24 months from submission to approval. Class III devices, particularly those requiring NMPA facility inspection or local clinical trials, can take 3 to 5 years or longer.
Key factors that influence the timeline include the completeness and quality of the submission dossier, whether clinical trials in China are required, the responsiveness of the NMPA review team, the need for facility inspection scheduling, and whether any questions or deficiency letters are raised during review. Submissions that are incomplete or poorly translated are a leading cause of delays.
Planning well in advance, preparing a complete and well-organized dossier, and engaging experienced regulatory support early in the process are the most effective ways to avoid avoidable delays in accessing the China medical device market.
How Starodub supports your China medical device market access
Navigating China’s medical device regulatory requirements demands both strategic planning and meticulous technical preparation. At Starodub, we support biopharmaceutical and medical device companies at every stage of their China market access journey, from initial classification strategy to post-market compliance. Our regulatory affairs specialists bring hands-on experience with NMPA submissions and understand the practical realities of what reviewers expect.
We can assist you with:
- Device classification determination and regulatory pathway strategy for the China medical device market
- Preparation and translation of registration dossiers aligned with NMPA requirements
- Clinical evaluation reports and clinical data gap analysis
- Coordination with China-based authorized representatives
- Labelling review and Mandarin-language documentation support
- Post-market surveillance planning and variation management
Whether you are entering China for the first time or managing an existing registration, we provide clear guidance and practical support to keep your project on track. Contact us today to discuss your China registration requirements and find out how we can help you achieve NMPA approval efficiently.
Related Articles
- How does Brazil's ANVISA approval process work for foreign companies?
- How do you integrate quality by design into regulatory strategy?
- How do regulatory strategies change for combination products?
- How do breakthrough device designations accelerate regulatory approval?
- How do you maintain regulatory compliance after approval?
